Stem cell firm Mesoblast pins hopes on Japanese regulatory change

November 25, 2013

Australian biotech firm Mesoblast is excited by this week’s legislative changes in Japan that will allow fast tracked approvals of stem cell products. Mesoblast is the world’s biggest player in the biotechnology sector, with potential therapies made from adult stem cells. This week Japan’s Diet passed bills to ensure the safety of regenerative medicine and to enable swift medical treatment using stem cells. (ABC.net)